Oncology Corporate Profile
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|TPIV 110||immunotherapy||Breast Cancer||II|
|TPIV 200||immunotherapy||Platinum-resistant Ovarian cancer||II|
|TPIV 200||immunotherapy||Platinum-sensitive Ovarian cancer||II|
|TPIV 200||immunotherapy||Triple negative Breast cancer||II|
View additional information on product candidates here »
3/24/2017 12:03 pm
[Marketwired] - NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...
3/22/2017 03:00 pm
[PR Newswire] - JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...
3/18/2017 05:00 pm